Assessing Hemophilia A Patient and Physician Reasons and Expectations for Switching Treatment to Kovaltry: A Nested Study Within an Existing Registry
Phase of Trial: Phase IV
Latest Information Update: 03 Sep 2019
Price : $35 *
At a glance
- Drugs Octocog alfa (Primary)
- Indications Haemophilia A
- Focus Therapeutic Use
- Sponsors Bayer
- 23 Aug 2019 Planned End Date changed from 30 Apr 2022 to 31 Dec 2021.
- 23 Aug 2018 Status changed from not yet recruiting to recruiting.
- 31 Jul 2018 New trial record